Intelligence · INN directory
Immunology Drugs Directory
Autoimmune and immunology biologics — anti-TNF, IL inhibitors, JAK inhibitors, and immunology pipeline assets.
Quick answer
Immunology & autoimmune drugs: NovaPharmaNews indexes 63 pharmaceutical drugs in this therapeutic segment with regulatory status, pipeline programs, patents, and congress coverage cross-links. Autoimmune and immunology biologics — anti-TNF, IL inhibitors, JAK inhibitors, and immunology pipeline assets.
-
nemolizumab
NEMLUVIO
D11AH12 -
nogapendekin alfa inbakicept
ANKTIVA
L03AC03 -
risankizumab
SKYRIZI AbbVie
L04AC18 -
ritlecitinib
LITFULO
L04AF08 -
sirukumab
PLIVENSIA
L04AC -
tagraxofusp
ELZONRIS
L01XX67 -
aldesleukin
PROLEUKIN
-
denileukin diftitox
ONTAK
-
filgotinib maleate
JYSELECA
-
upadacitinib hydrate
RINVOQ PARTIAL CHANGE APPROVAL
-
dupixent
-
interleukin
-
interleukin-
-
jaktinib hydrochloride tablets
-
tegafur-gimeracil-oteracil
Frequently asked questions
How many immunology & autoimmune drugs are in the directory?
63 drug profiles match this therapeutic area filter based on class, mechanism, target, and INN metadata.
How are drugs assigned to a therapeutic area?
Classification uses WHO therapeutic class, mechanism of action, molecular target, and INN pattern matching against curated oncology, metabolic, CNS, rare disease, and immunology taxonomies.
Where does regulatory data come from?
Profiles combine FDA Drugs@FDA, EMA EPAR references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence.